{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=85", "query": { "intervention": "Placebo Intravenous", "page": 85 }, "page_size": 10 }, "pagination": { "page": 85, "page_size": 10, "total_count": 2348, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=86&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=84&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T06:00:47.934Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03662542", "title": "A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Guselkumab Dose 1", "type": "DRUG" }, { "name": "Guselkumab Dose 2", "type": "DRUG" }, { "name": "Golimumab Dose 1", "type": "DRUG" }, { "name": "Golimumab Dose 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 214, "start_date": "2018-11-20", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 14, "location_summary": "San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662542" }, { "nct_id": "NCT01071083", "title": "Treatment Interruption of Natalizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "natalizumab", "type": "DRUG" }, { "name": "interferon beta 1-a", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "IV placebo", "type": "OTHER" }, { "name": "glatiramer acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 175, "start_date": "2010-03", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-09-19", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 20, "location_summary": "Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071083" }, { "nct_id": "NCT01932554", "title": "Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Hb-SS Disease With Vasoocclusive Pain", "Hemoglobin SS Disease With Vasoocclusive Crisis", "Other Sickle Cell Disease With Vaso-Occlusive Pain", "Hemoglobin SS Disease With Crisis" ], "interventions": [ { "name": "Abciximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Intravenous hydration", "type": "OTHER" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Parenteral narcotic", "type": "DRUG" }, { "name": "Incentive spirometry", "type": "OTHER" }, { "name": "Supplemental oxygen", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "St. Louis University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "5 Years to 25 Years" }, "enrollment_count": 0, "start_date": "2013-11", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-03-26", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01932554" }, { "nct_id": "NCT05305222", "title": "A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 17, "start_date": "2017-10-23", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05305222" }, { "nct_id": "NCT00110994", "title": "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Melanoma" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2005-04", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 14, "location_summary": "Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110994" }, { "nct_id": "NCT02856594", "title": "Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Postoperative Delirium", "Sleep", "Anesthesia" ], "interventions": [ { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 469, "start_date": "2017-03-06", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02856594" }, { "nct_id": "NCT03705169", "title": "Pharmacokinetics and Safety of SAR441236", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "SAR441236", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 52, "start_date": "2019-05-20", "completion_date": "2022-04-04", "has_results": true, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03705169" }, { "nct_id": "NCT04666441", "title": "COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "REGN10933+REGN10987 combination therapy", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1149, "start_date": "2020-12-15", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 57, "location_summary": "Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666441" }, { "nct_id": "NCT03831945", "title": "Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "VRC-HIVMAB060-00-AB (VRC01)", "type": "BIOLOGICAL" }, { "name": "10-1074", "type": "BIOLOGICAL" }, { "name": "Normal Saline Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2019-04-04", "completion_date": "2020-12-08", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03831945" }, { "nct_id": "NCT01677572", "title": "Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 197, "start_date": "2012-10-05", "completion_date": "2019-07-31", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-24T06:00:47.934Z", "location_count": 32, "location_summary": "Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677572" } ] }